Form 4: Organon R&D Head Reports Routine Stock Transactions

Organon's Head of R&D and CMO, Juan Camilo Arjona Ferreira, reported the acquisition of common stock through RSU vesting and subsequent sale for tax withholding.

Summary

• Juan Camilo Arjona Ferreira, Organon & Co.'s Head of R&D and CMO, reported transactions involving the company's common stock.
• On November 7, 2025, 6,446 shares of common stock were acquired through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 2,307 shares of common stock were disposed of at a price of $6.71 per share to cover tax obligations related to the RSU vesting.
• Following these transactions, the reporting person beneficially owns 28,916.355 shares of Organon & Co. common stock directly.
• Additionally, 6,447 Restricted Stock Units remain beneficially owned, representing a contingent right to receive an equal number of common shares, scheduled to vest on November 7, 2026.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving RSU vesting and tax-related share disposition, which is a neutral event reflecting standard executive compensation and tax practices rather than a significant positive or negative operational or strategic development for the company.

Positives

• The acquisition of 6,446 shares of common stock through RSU vesting indicates a component of executive compensation being realized.
• The net effect of the reported transactions on November 7, 2025, was an increase in the reporting person's direct beneficial ownership of common stock by 4,139 shares (6,446 acquired 2,307 disposed).

Negatives

• A portion of the vested shares (2,307 shares) was sold to cover tax liabilities, which is a common practice but reduces the immediate increase in the insider's direct holdings.

Future Outlook

The filing indicates future vesting events for Restricted Stock Units, with 6,447 units scheduled to vest on November 7, 2026.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of Restricted Stock Units and subsequent tax-related share disposition. Such transactions are common across all industries for publicly traded companies with equity compensation plans.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event for an executive, not indicative of a change in company fundamentals or strategy.
• Employees: Reflects standard executive compensation practices, which may be part of broader company-wide equity incentive programs.

Next Steps

• The remaining 6,447 Restricted Stock Units are scheduled to vest on November 7, 2026, at which point they will be distributed as shares of Organon & Co. common stock.

Key Dates

Keywords

Organon & Co., OGN, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Common Stock, Executive Compensation, Juan Camilo Arjona Ferreira